nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2008 | Original Article

Evaluation of [¹⁸F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors

verfasst von: Helen Su, Yann Seimbille, Gregory Z. Ferl, Claudia Bodenstein, Barbara Fueger, Kevin J. Kim, Yu-Tien Hsu, Steven M. Dubinett, Michael E. Phelps, Johannes Czernin, Wolfgang A. Weber

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gefitinib, an inhibitor of the epidermal growth factor receptor–tyrosine kinase (EGFR-TK), has shown potent effects in a subset of patients carrying specific EGFR-TK mutations in advanced non-small-cell lung cancer. In this study, we asked whether PET with [¹⁸F]gefitinib may be used to study noninvasively the pharmacokinetics of gefitinib in vivo and to image the EGFR status of cancer cells.

Materials and methods

Synthesis of [¹⁸F]gefitinib has been previously described. The biodistribution and metabolic stability of [¹⁸F]gefitinib was assessed in mice and vervet monkeys for up to 2 h post injection by both micropositron emission tomography (PET)/computed tomography (CT) scans and postmortem ex vivo tissue harvesting. Uptake levels of radiolabeled gefitinib in EGFR-expressing human cancer cell lines with various levels of EGFR expression or mutation status were evaluated both in vivo and in vitro.

Results

MicroPET/CT scans in two species demonstrated a rapid and predominantly hepatobiliary clearance of [¹⁸F]gefitinib in vivo. However, uptake levels of radiolabeled gefitinib, both in vivo and in vitro, did not correlate with EGFR expression levels or functional status. This unexpected observation was due to high nonspecific, nonsaturable cellular uptake of gefitinib.

Conclusion

The biodistribution of the drug analogue [¹⁸F]gefitinib suggests that it may be used to assess noninvasively the pharmacokinetics of gefitinib in patients by PET imaging. This is of clinical relevance, as insufficient intratumoral drug concentrations are considered to be a factor for resistance to gefitinib therapy. However, the highly nonspecific cellular binding of [¹⁸F]gefitinib may preclude the use of this imaging probe for noninvasive assessment of EGFR receptor status in patients.

Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23:2556–68.PubMedCrossRef

Saba NF, Khuri FR, Shin DM. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology. 2006;20:153–61.PubMed

Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev. 2006;32:74–89.PubMedCrossRef

Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20:1S–13S.PubMed

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama. 2003;290:2149–58.PubMedCrossRef

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237–46.PubMedCrossRef

Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62:5749–54.PubMed

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRef

Cappuzzo F, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, et al. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol. 2006;58:31–45.PubMedCrossRef

10.

Fowler JS, Ding YS, Volkow ND. Radiotracers for positron emission tomography imaging. Semin Nucl Med. 2003;33:14–27.PubMedCrossRef

11.

Murali D, Flores LG, Converse AK, Barlett RM, Barnhart TE, Armstrong EA, et al. Evaluation of [F-18]Iressa as aPET imaging agent for tumor overexpressing epidermal growth factor (EGFR) receptors. J Labelled Compd Radiopharm. 2005;48:S1–S341.CrossRef

12.

Seimbille Y, Phelps ME, Czernin J, Silverman DS. Fluorin-18 labeling of 6,7-distributed anilinoquinazoline derivatives, for positron emission tomography (PET) imaging of tyrosine kianse receptors:synthesis of 18F-Iressa and related molecular probes.J Labelled Compd Radiopharm. 2005;48:819–27.CrossRef

13.

Holt DP, Ravert HT, Dannals RF, Pomper MG. Synthesis of [11C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. J Labelled Compd Radiopharm. 2006;49:883–8.CrossRef

14.

Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2006;16:4102–6.PubMedCrossRef

15.

Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet. 2005;44:1165–77.PubMedCrossRef

16.

Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol. 2006;7:499–507.PubMedCrossRef

17.

Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, gefitinib). Cancer Res. 2005;65:1770–7.PubMedCrossRef

18.

Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med. 2005;46:455–63.PubMed

19.

Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131–7.PubMedCrossRef

20.

Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med. 1997;38:1614–23.PubMed

21.

Ortu G, Ben-David I, Rozen Y, Freedman NM, Chisin R, Levitzki A, et al. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer. 2002;101:360–70.PubMedCrossRef

22.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–24.PubMedCrossRef

23.

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.PubMedCrossRef

24.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.PubMedCrossRef

25.

Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027–32.PubMed

26.

Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226–35.PubMed

27.

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.PubMedCrossRef

28.

Huang SC, Truong D, Wu HM, Chatziioannou AF, Shao W, Wu AM, et al. An internet-based “kinetic imaging system” (KIS) for MicroPET. Mol Imaging Biol. 2005;7:330–41.PubMedCrossRef

29.

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.PubMedCrossRef

30.

Senekowitsch-Schmidtke R, Steiner K, Haunschild J, Mollenstadt S, Truckenbrodt R. In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425. Cancer Immunol Immunother. 1996;42:108–14.PubMedCrossRef

31.

Eckelman WC. The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals. Nucl Med Biol. 1994;21:759–69.PubMedCrossRef

32.

Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NM, Chisin R, et al. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol. 2001;28:359–74.PubMedCrossRef

33.

McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2005;4:641–9.PubMedCrossRef

34.

Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, et al. Cellular targets of gefitinib. Cancer Res. 2005;65:379–82.PubMed

35.

Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–7.PubMedCrossRef

36.

Pal A, Glekas A, Doubrovin M, Balatoni J, Beresten T, Maxwell D, et al. Molecular Imaging of EGFR Kinase Activity in Tumors with (124)I-Labeled Small Molecular Tracer and Positron Emission Tomography. Mol Imaging Biol. 2006;8:262–77.PubMedCrossRef

Titel: Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
verfasst von: Helen Su
Yann Seimbille
Gregory Z. Ferl
Claudia Bodenstein
Barbara Fueger
Kevin J. Kim
Yu-Tien Hsu
Steven M. Dubinett
Michael E. Phelps
Johannes Czernin
Wolfgang A. Weber
Publikationsdatum: 01.06.2008
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0636-6

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

Scintigraphy or fine-needle aspiration biopsy to exclude thyroid malignancy: what should be done first in iodine deficiency?

CT Teaching Manual: A systematic approach to CT reading (3rd edn.). Matthias Hofer (Ed)

Differences in radiosensitivity between three HER2 overexpressing cell lines

An imaging analysis of 99mTc-UBI (29–41) uptake in S. aureus infected thighs of rabbits on ciprofloxacin treatment

TSH alone is not sufficient to exclude all patients with a functioning thyroid nodule from undergoing testing to exclude thyroid cancer

Optimisation of protocol for low dose CT-derived attenuation correction in myocardial perfusion SPECT imaging